For long-term storage, freezing is recommended
It is generally well-tolerated, with minimal side effects such as mild headache or injection site irritation
We strongly recommend consulting with our qualified healthcare professionals before beginning IV therapy
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
10% on your entire order when you pay with crypto USDT USDC BTC & more CJC-1295 (no DAC)/Ipamorelin 10MG 1,800.00 Buy CJC-1295 (no DAC) / Ipamorelin 10mg in Bangkok with same-day collection pre-mixed research peptide pairing (5mg CJC-1295 + 5mg Ipamorelin per vial)
Introduction to Growth Hormone Releasing Hormone (GHRH) Peptides CJC-1295 and Ipamorelin are commonly grouped together because they both influence growth hormone pathways, yet they do so through different mechanisms
